Atypical hemolytic uremic syndrome

Seminars in Nephrology

Volumn 33, Issue 6, 2013, Pages 508-530

  Kavanagh, David ^a   Goodship, Tim H ^a   Richards, Anna ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Complement; Eculizumab; Factor H; Factor I; Hemolytic uremic syndrome; Membrane cofactor protein; Thrombomodulin; Transplantation

Indexed keywords

AUTOANTIBODY; COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; ECULIZUMAB; MEMBRANE COFACTOR PROTEIN; THROMBOMODULIN;

ACUTE KIDNEY FAILURE; ARTICLE; COMPLEMENT FACTOR H GENE; COMPLEMENT FACTOR I GENE; COMPLEMENT SYSTEM; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOPATHOGENESIS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LIVING DONOR; MCP GENE; MUTATIONAL ANALYSIS; PENETRANCE; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS;

COMPLEMENT; ECULIZUMAB; FACTOR H; FACTOR I; HEMOLYTIC UREMIC SYNDROME; MEMBRANE COFACTOR PROTEIN; THROMBOMODULIN; TRANSPLANTATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; AUTOANTIBODIES; COMPLEMENT ACTIVATION; COMPLEMENT FACTOR H; COMPLEMENT SYSTEM PROTEINS; HEMOLYTIC-UREMIC SYNDROME; HUMANS; KIDNEY TRANSPLANTATION; PRECIPITATING FACTORS;

EID: 84886250055     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2013.08.003     Document Type: Article

References (227)

1. Kavanagh D., Richards A., Atkinson J. Complement regulatory genes and hemolytic uremic syndromes. Annu Rev Med 2008, 59:293-309.
2. Besbas N., Karpman D., Landau D., Loirat C., Proesmans W., Remuzzi G., et al. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int 2006, 70:423-431.
3. Constantinescu A.R., Bitzan M., Weiss L.S., Christen E., Kaplan B.S., Cnaan A., et al. Non-enteropathic hemolytic uremic syndrome: causes and short-term course. Am J Kidney Dis 2004, 43:976-982.
4. Fogo A., Kashgarian M. Diagnostic atlas of renal pathology 2005, Elsevier Science, Amsterdam.
5. Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010, 11:785-797.
6. Kemper C., Atkinson J.P. T-cell regulation: with complements from innate immunity. Nat Rev Immunol 2007, 7:9-18.
7. Warwicker P., Goodship T.H., Donne R.L., Pirson Y., Nicholls A., Ward R.M., et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 1998, 53:836-844.
8. Richards A., Buddles M.R., Donne R.L., Kaplan B.S., Kirk E., Venning M.C., et al. Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition. Am J Hum Genet 2001, 68:485-490.
9. Fan X., Yoshida Y., Honda S., Matsumoto M., Sawada Y., Hattori M., et al. Analysis of genetic and predisposing factors in Japanese patients with atypical hemolytic uremic syndrome. Mol Immunol 2013, 54:238-246.
10. Geerdink L.M., Westra D., van Wijk J.A., Dorresteijn E.M., Lilien M.R., Davin J.C., et al. Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. Pediatr Nephrol 2012, 27:1283-1291.
11. Maga T.K., Nishimura C.J., Weaver A.E., Frees K.L., Smith R.J. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat 2010, 31:E1445-E1460.
12. Neumann H.P., Salzmann M., Bohnert-Iwan B., Mannuelian T., Skerka C., Lenk D., et al. Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries. J Med Genet 2003, 40:676-681.
13. Caprioli J., Bettinaglio P., Zipfel P.F., Amadei B., Daina E., Gamba S., et al. The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol 2001, 12:297-307.
14. Perez-Caballero D., Gonzalez-Rubio C., Gallardo M.E., Vera M., Lopez-Trascasa M., Rodriguez de Cordoba S., et al. Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am J Hum Genet 2001, 68:478-484.
15. Dragon-Durey M.A., Fremeaux-Bacchi V., Loirat C., Blouin J., Niaudet P., Deschenes G., et al. Heterozygous and homozygous factor h deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol 2004, 15:787-795.
16. Richards A., Kavanagh D., Atkinson J.P. Inherited complement regulatory protein deficiency predisposes to human disease in acute injury and chronic inflammatory statesthe examples of vascular damage in atypical hemolytic uremic syndrome and debris accumulation in age-related macular degeneration. Adv Immunol 2007, 96:141-177.
17. Schmidt C.Q., Herbert A.P., Kavanagh D., Gandy C., Fenton C.J., Blaum B.S., et al. A new map of glycosaminoglycan and C3b binding sites on factor H. J Immunol 2008, 181:2610-2619.
18. Ferreira V.P., Pangburn M.K., Cortes C. Complement control protein factor H: the good, the bad, and the inadequate. Mol Immunol 2010, 47:2187-2197.
19. Clark S.J., Ridge L.A., Herbert A.P., Hakobyan S., Mulloy B., Wurzner R., et al. Tissue-specific host recognition by complement factor H is mediated by differential activities of its glycoaminoglycans-binding regions. J Immunol 2013, 190:2049-2057.
20. Weismann D., Hartvigsen K., Lauer N., Bennett K.L., Scholl H.P., Charbel Issa P., et al. Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature 2011, 478:76-81.
21. Sjoberg A.P., Trouw L.A., Clark S.J., Sjolander J., Heinegard D., Sim R.B., et al. The factor H variant associated with age-related macular degeneration (His-384) and the non-disease-associated form bind differentially to C-reactive protein, fibromodulin, DNA, and necrotic cells. J Biol Chem 2007, 282:10894-10900.
22. Laine M., Jarva H., Seitsonen S., Haapasalo K., Lehtinen M.J., Lindeman N., et al. Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein. J Immunol 2007, 178:3831-3836.
23. Hakobyan S., Harris C.L., van den Berg C.W., Fernandez-Alonso M.C., de Jorge E.G., de Cordoba S.R., et al. Complement factor H binds to denatured rather than to native pentameric C-reactive protein. J Biol Chem 2008, 283:30451-30460.
24. Kopp A., Strobel S., Tortajada A., Rodriguez de Cordoba S., Sanchez-Corral P., Prohaszka Z, et al. Atypical hemolytic uremic syndrome-associated variants and autoantibodies impair binding of factor h and factor h-related protein 1 to pentraxin 3. J Immunol 2012, 189:1858-1867.
25. Ferreira V.P., Herbert A.P., Cortes C., McKee K.A., Blaum B.S., Esswein S.T., et al. The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome. J Immunol 2009, 182:7009-7018.
26. Abarrategui-Garrido C., Melgosa M., Pena-Carrion A., de Jorge E.G., de Cordoba S.R., Lopez-Trascasa M., et al. Mutations in proteins of the alternative pathway of complement and the pathogenesis of atypical hemolytic uremic syndrome. Am J Kidney Dis 2008, 52:171-180.
27. Vaziri-Sani F., Holmberg L., Sjoholm A.G., Kristoffersson A.C., Manea M., Fremeaux-Bacchi V., et al. Phenotypic expression of factor H mutations in patients with atypical hemolytic uremic syndrome. Kidney Int 2006, 69:981-988.
28. Stahl A.L., Vaziri-Sani F., Heinen S., Kristoffersson A.C., Gydell K.H., Raafat R., et al. Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood 2008, 111:5307-5315.
29. Pechtl I.C., Kavanagh D., McIntosh N., Harris C.L., Barlow P.N. Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities. J Biol Chem 2011, 286:11082-11090.
30. Tortajada A., Pinto S., Martinez-Ara J., Lopez-Trascasa M., Sanchez-Corral P., de Cordoba S.R. Complement factor H variants I890 and L1007 while commonly associated with atypical hemolytic uremic syndrome are polymorphisms with no functional significance. Kidney Int 2012, 81:56-63.
31. Heinen S., Sanchez-Corral P., Jackson M.S., Strain L., Goodship J.A., Kemp E.J., et al. De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome. Hum Mutat 2006, 27:292-293.
32. Venables J.P., Strain L., Routledge D., Bourn D., Powell H.M., Warwicker P., et al. Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med 2006, 3:e431.
33. Francis N.J., McNicholas B., Awan A., Waldron M., Reddan D., Sadlier D., et al. A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome. Blood 2012, 119:591-601.
34. Pickering M.C., de Jorge E.G., Martinez-Barricarte R., Recalde S., Garcia-Layana A., Rose K.L., et al. Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med 2007, 204:1249-1256.
35. Richards A., Kavanagh D. Pathogenesis of thrombotic microangiopathy: insights from animal models. Nephron Exp Nephrol 2009, 113:e97-103.
36. Goicoechea de Jorge E., Macor P., Paixao-Cavalcante D., Rose K.L., Tedesco F., Cook H.T., et al. The development of atypical hemolytic uremic syndrome depends on complement C5. J Am Soc Nephrol 2011, 22:137-145.
37. Fremeaux-Bacchi V., Dragon-Durey M.A., Blouin J., Vigneau C., Kuypers D., Boudailliez B., et al. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet 2004, 41:e84.
38. Kavanagh D., Kemp E.J., Mayland E., Winney R.J., Duffield J.S., Warwick G., et al. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005, 16:2150-2155.
39. Kavanagh D., Richards A., Noris M., Hauhart R., Liszewski M.K., Karpman D., et al. Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Mol Immunol 2008, 45:95-105.
40. Caprioli J., Noris M., Brioschi S., Pianetti G., Castelletti F., Bettinaglio P., et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006, 108:1267-1279.
41. Nilsson S.C., Kalchishkova N., Trouw L.A., Fremeaux-Bacchi V., Villoutreix B.O., Blom A.M. Mutations in complement factor I as found in atypical hemolytic uremic syndrome lead to either altered secretion or altered function of factor I. Eur J Immunol 2010, 40:172-185.
42. Nilsson S.C., Karpman D., Vaziri-Sani F., Kristoffersson A.C., Salomon R., Provot F., et al. A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation. Mol Immunol 2007, 44:1835-1844.
43. Westra D., Volokhina E., van der Heijden E., Vos A., Huigen M., Jansen J., et al. Genetic disorders in complement (regulating) genes in patients with atypical haemolytic uraemic syndrome (aHUS). Nephrol Dial Transplant 2010, 25:2195-2202.
44. Sullivan M., Erlic Z., Hoffmann M.M., Arbeiter K., Patzer L., Budde K., et al. Epidemiological approach to identifying genetic predispositions for atypical hemolytic uremic syndrome. Ann Hum Genet 2010, 74:17-26.
45. Richards A., Kemp E.J., Liszewski M.K., Goodship J.A., Lampe A.K., Decorte R., et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2003, 100:12966-12971.
46. Bresin E., Rurali E., Caprioli J., Sanchez-Corral P., Fremeaux-Bacchi V., Rodriguez de Cordoba S., et al. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol 2013, 24:475-486.
47. Fremeaux-Bacchi V., Moulton E.A., Kavanagh D., Dragon-Durey M.A., Blouin J., Caudy A., et al. Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2006, 17:2017-2025.
48. Richards A., Liszewski K.M., Kavanagh D., Fang C.J., Moulton E., Fremeaux-Bacchi V., et al. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol Immunol 2007, 44:111-122.
49. Fremeaux-Bacchi V., Fakhouri F., Garnier A., Bienaime F., Dragon-Durey M.A., Ngo S., et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide french series comparing children and adults. Clin J Am Soc Nephrol 2013, 8:554-562.
50. Fremeaux-Bacchi V., Miller E.C., Liszewski M.K., Strain L., Blouin J., Brown A.L., et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 2008, 112:4948-4952.
51. Noris M., Caprioli J., Bresin E., Mossali C., Pianetti G., Gamba S., et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010, 5:1844-1859.
52. Sartz L., Olin A.I., Kristoffersson A.C., Stahl A.L., Johansson M.E., Westman K., et al. A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome. J Immunol 2012, 188:2030-2037.
53. Lhotta K., Janecke A.R., Scheiring J., Petzlberger B., Giner T., Fally V., et al. A large family with a gain-of-function mutation of complement C3 predisposing to atypical hemolytic uremic syndrome, microhematuria, hypertension and chronic renal failure. Clin J Am Soc Nephrol 2009, 4:1356-1362.
54. Roumenina L.T., Frimat M., Miller E.C., Provot F., Dragon-Durey M.A., Bordereau P., et al. A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood 2012, 119:4182-4191.
55. Roumenina L.T., Jablonski M., Hue C., Blouin J., Dimitrov J.D., Dragon-Durey M.A., et al. Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood 2009, 114:2837-2845.
56. Goicoechea de Jorge E., Harris C.L., Esparza-Gordillo J., Carreras L., Arranz E.A., Garrido C.A., et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2007, 104:240-245.
57. Kavanagh D., Kemp E.J., Richards A., Burgess R.M., Mayland E., Goodship J.A., et al. Does complement factor B have a role in the pathogenesis of atypical HUS?. Mol Immunol 2006, 43:856-859.
58. Tawadrous H., Maga T., Sharma J., Kupferman J., Smith R.J., Schoeneman M. A novel mutation in the complement factor B gene (CFB) and atypical hemolytic uremic syndrome. Pediatr Nephrol 2010, 25:947-951.
59. Weiler H., Isermann B.H. Thrombomodulin. J Thromb Haemost 2003, 1:1515-1524.
60. Delvaeye M., Noris M., De Vriese A., Esmon C.T., Esmon N.L., Ferrell G., et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009, 361:345-357.
61. Westra D., Vernon K.A., Volokhina E.B., Pickering M.C., van de Kar N.C., van den Heuvel L.P. Atypical hemolytic uremic syndrome and genetic aberrations in the complement factor H-related 5 gene. J Hum Genet 2012, 57:459-464.
62. Monteferrante G., Brioschi S., Caprioli J., Pianetti G., Bettinaglio P., Bresin E., et al. Genetic analysis of the complement factor H related 5 gene in haemolytic uraemic syndrome. Mol Immunol 2007, 44:1704-1708.
63. Stahl A.L., Kristoffersson A., Olin A.I., Olsson M.L., Roodhooft A.M., Proesmans W., et al. A novel mutation in the complement regulator clusterin in recurrent hemolytic uremic syndrome. Mol Immunol 2009, 46:2236-2243.
64. Abarrategui-Garrido C., Martinez-Barricarte R., Lopez-Trascasa M., de Cordoba S.R., Sanchez-Corral P. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood 2009, 114:4261-4271.
65. Dragon-Durey M.A., Sethi S.K., Bagga A., Blanc C., Blouin J., Ranchin B., et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 2010, 21:2180-2187.
66. Jozsi M., Licht C., Strobel S., Zipfel S.L., Richter H., Heinen S., et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 2008, 111:1512-1514.
67. Moore I., Strain L., Pappworth I., Kavanagh D., Barlow P.N., Herbert A.P., et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 2010, 115:379-387.
68. Foltyn Zadura A., Zipfel P.F., Bokarewa M.I., Sturfelt G., Jonsen A., Nilsson S.C., et al. Factor H autoantibodies and deletion of complement factor H-related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndrome. Arthritis Res Ther 2012, 14:R185.
69. Hofer J., Janecke A.R., Zimmerhackl L.B., Riedl M., Rosales A., Giner T., et al. Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2013, 8:407-415.
70. Zipfel P.F., Edey M., Heinen S., Jozsi M., Richter H., Misselwitz J., et al. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet 2007, 3:e41.
71. Abarrategui-Garrido C., Martinez-Barricarte R., Lopez-Trascasa M., Rodriguez de Cordoba S., Sanchez-Corral P. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood 2009, 114:4261-4271.
72. Moore I., Strain L., Pappworth I., Kavanagh D., Barlow P.N., Herbert A.P., et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4 and with mutations in CFH, CFI, CD46 and C3 in patients with atypical haemolytic uraemic syndrome. Blood 2010, 115:379-387.
73. Dragon-Durey M.A., Blanc C., Marliot F., Loirat C., Blouin J., Sautes-Fridman C., et al. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J Med Genet 2009, 46:447-450.
74. Strobel S., Abarrategui-Garrido C., Fariza-Requejo E., Seeberger H., Sanchez-Corral P., Jozsi M. Factor H-related protein 1 neutralizes anti-factor H autoantibodies in autoimmune hemolytic uremic syndrome. Kidney Int 2011, 80:397-404.
75. Jozsi M., Strobel S., Dahse H.M., Liu W.S., Hoyer P.F., Oppermann M., et al. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood 2007, 110:1516-1518.
76. Dragon-Durey M.A., Loirat C., Cloarec S., Macher M.A., Blouin J., Nivet H., et al. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005, 16:555-563.
77. Blanc C., Roumenina L.T., Ashraf Y., Hyvarinen S., Sethi S.K., Ranchin B., et al. Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome. J Immunol 2012, 189:3528-3537.
78. Kavanagh D., Pappworth I.Y., Anderson H., Hayes C.M., Moore I., Hunze E.M., et al. Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon?. Clin J Am Soc Nephrol 2012, 7:417-426.
79. Caprioli J., Castelletti F., Bucchioni S., Bettinaglio P., Bresin E., Pianetti G., et al. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet 2003, 12:3385-3395.
80. Esparza-Gordillo J., Goicoechea de Jorge E., Buil A., Carreras Berges L., Lopez-Trascasa M., Sanchez-Corral P., et al. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet 2005, 14:703-712.
81. Fremeaux-Bacchi V., Kemp E.J., Goodship J.A., Dragon-Durey M.A., Strain L., Loirat C., et al. The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts. J Med Genet 2005, 42:852-856.
82. Ermini L., Goodship T.H., Strain L., Weale M.E., Sacks S.H., Cordell H.J., et al. Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with aHUS. Mol Immunol 2012, 49:640-648.
83. Harris C.L., Heurich M., Rodriguez de Cordoba S., Morgan B.P. The complotype: dictating risk for inflammation and infection. Trends Immunol 2012, 33:513-521.
84. Tortajada A., Montes T., Martinez-Barricarte R., Morgan B.P., Harris C.L. de Cordoba SR. The disease-protective complement factor H allotypic variant Ile62 shows increased binding affinity for C3b and enhanced cofactor activity. Hum Mol Genet 2009, 18:3452-3461.
85. Hocking H.G., Herbert A.P., Kavanagh D., Soares D.C., Ferreira V.P., Pangburn M.K., et al. Structure of the N-terminal region of complement factor H and conformational implications of disease-linked sequence variations. J Biol Chem 2008, 283:9475-9487.
86. Esparza-Gordillo J., Jorge E.G., Garrido C.A., Carreras L., Lopez-Trascasa M., Sanchez-Corral P., et al. Insights into hemolytic uremic syndrome: segregation of three independent predisposition factors in a large, multiple affected pedigree. Mol Immunol 2006, 43:1769-1775.
87. Frimat M., Roumenina L., Tabarin F., Halbwachs-Mecarelli L., Fremeaux-Bacchi V. Membrane cofactor protein (MCP) haplotype, which predisposes to atypical hemolytic and uremic syndrome, has no consequence on neutrophils and endothelial cells MCP levels or on HUVECs ability to activate complement. Immunobiology 2012, 217:1187-1188.
88. Blom A.M., Bergstrom F., Edey M., Diaz-Torres M., Kavanagh D., Lampe A., et al. A novel non-synonymous polymorphism (p.Arg240His) in C4b-binding protein is associated with atypical hemolytic uremic syndrome and leads to impaired alternative pathway cofactor activity. J Immunol 2008, 180:6385-6391.
89. Martinez-Barricarte R., Goicoechea de Jorge E., Montes T., Layana A.G., Rodriguez de Cordoba S. Lack of association between polymorphisms in C4b-binding protein and atypical haemolytic uraemic syndrome in the Spanish population. Clin Exp Immunol 2009, 155:59-64.
90. Kavanagh D., Goodship T. Genetics and complement in atypical HUS. Pediatr Nephrol 2010, 25:2431-2442.
91. Sullivan M., Rybicki L.A., Winter A., Hoffmann M.M., Reiermann S., Linke H., et al. Age-related penetrance of hereditary atypical hemolytic uremic syndrome. Ann Hum Genet 2011, 75:639-647.
92. Cruzado J.M., de Cordoba S.R., Melilli E., Bestard O., Rama I., Sanchez-Corral P., et al. Successful renal transplantation in a patient with atypical hemolytic uremic syndrome carrying mutations in both factor I and MCP. Am J Transplant 2009, 9:1477-1483.
93. Bienaime F., Dragon-Durey M.A., Regnier C.H., Nilsson S.C., Kwan W.H., Blouin J., et al. Mutations in components of complement influence the outcome of factor I-associated atypical hemolytic uremic syndrome. Kidney Int 2010, 77:339-349.
94. Sellier-Leclerc A.L., Fremeaux-Bacchi V., Dragon-Durey M.A., Macher M.A., Niaudet P., Guest G., et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2007, 18:2392-2400.
95. Edey M.M., Mead P.A., Saunders R.E., Strain L., Perkins S.J., Goodship T.H., et al. Association of a factor H mutation with hemolytic uremic syndrome following a diarrheal illness. Am J Kidney Dis 2008, 51:487-490.
96. Fakhouri F., Roumenina L., Provot F., Sallee M., Caillard S., Couzi L., et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol 2010, 21:859-867.
97. Goodship T.H., Kavanagh D. Pulling the trigger in atypical hemolytic uremic syndrome: the role of pregnancy. J Am Soc Nephrol 2010, 21:731-732.
98. Fakhouri F., Roumenina L., Provot F., Sallee M., Caillard S., Couzi L., et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol 2010, 21:859-867.
99. Le Quintrec M., Zuber J., Moulin B., Kamar N., Jablonski M., Lionet A., et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 2013, 13:663-675.
100. Loirat C., Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011, 6:60.
101. Kavanagh D., Richards A., Fremeaux-Bacchi V., Noris M., Goodship T., Remuzzi G., et al. Screening for complement system abnormalities in patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2007, 2:591-596.
102. Kavanagh D., Anderson H.E. Interpretation of genetic variants of uncertain significance in atypical hemolytic uremic syndrome. Kidney Int 2012, 81:11-13.
103. Koehl B., Boyer O., Biebuyck-Gouge N., Kossorotoff M., Fremeaux-Bacchi V., Boddaert N., et al. Neurological involvement in a child with atypical hemolytic uremic syndrome. Pediatr Nephrol 2010, 25:2539-2542.
104. Ariceta G., Besbas N., Johnson S., Karpman D., Landau D., Licht C., et al. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 2009, 24:687-696.
105. Taylor C.M., Machin S., Wigmore S.J., Goodship T.H. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol 2010, 148:37-47.
106. Rother R.P., Rollins S.A., Mojcik C.F., Brodsky R.A., Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007, 25:1256-1264.
107. Gruppo R.A., Rother R.P. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 2009, 360:544-546.
108. Ariceta G., Arrizabalaga B., Aguirre M., Morteruel E., Lopez-Trascasa M. Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants. Am J Kidney Dis 2012, 59:707-710.
109. Dorresteijn E.M., van de Kar NCAJ, Cransberg K. Eculizumab as rescue therapy for atypical hemolytic uremic syndrome with normal platelet count. Pediatr Nephrol 2012, 27:1193-1195.
110. Lapeyraque A.-L., Fremeaux-Bacchi V., Robitaille P. Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome. Pediatr Nephrol 2011, 26:621-624.
111. Ohanian M., Cable C., Halka K. Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome. Clin Pharmacol 2011, 3:5-12.
112. Prescott H.C., Wu H.M., Cataland S.R., Baiocchi R.A. Eculizumab therapy in an adult with plasma exchange-refractory atypical hemolytic uremic syndrome. Am J Hematol 2010, 85:976-977.
113. Tschumi S., Gugger M., Bucher B.S., Riedl M., Simonetti G.D. Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings. Pediatr Nephrol 2011, 26:2085-2088.
114. Koese O., Zimmerhackl L.-B., Jungraithmayr T., Mache C., Nuernberger J. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab. Semin Thromb Hemost 2010, 36:669-672.
115. Kim JJ, Waller SC, Reid CJ. Eculizumab in atypical haemolytic-uraemic syndrome allows cessation of plasma exchange and dialysis. Clin Kidney J. 2012;5:34-6.
116. Malina M. Peripheral gangrene in children with atypical hemolytic uremic syndrome. Paper presented at: 44th Annual Meeting of the European Society for Pediatric Nephrology 14 Sept 2011 Dubrovnik, Croatia.
117. Fremont OT. Eculizumab treatment for aHUS in a child with positive family history. Paper presented at: 42nd Annual Meeting of the American Society of Nephrology. 27 Oct 2009 San Diego CA.
118. Garjau M. Early treatment with eculizumab may be beneficial in atypical haemolytic uraemic syndrome. Clin Kidney J 2012, 5:31-33.
119. Haffner K. Effective eculizumab therapy of familiar atypical HUS in a 4 year old patient Paper presented at: 2nd International Conference on HUS, MPGN and PNH 13 June 2010 Innsbruck, Austria.
120. Muus P. Safety and efficacy of eculizumab in aHUS patients on chronic plasma therapy: Interim analysis of a phase II trial. Paper presented at: 43rd Annual Meeting of the American Society of Nephrology November 16, 2010; Denver, CO.
121. Licht C. Phase II study of eculizumab in patients with atypical HUS receiving chronic plasma exchange/infusion. Paper presented at 44th Annual Meeting of the American Society of Nephrology November 8, 2011; Philadelphia, PA.
122. Greenbaum LA. Eculizumab is an effective long-term treatment in patients with atypical haemolytic uremic syndrome previously receiving chronic plasma exchange/infusion: extension study results. Presented at the 53rd Annual Meeting of the American Society of Hematology; December 10, 2011; San Diego, CA.
123. Muus PM. Safety and efficacy of eculizumab in aHUS patients on chronic plasma therapy: interim analysis of a phase II trial. Presented at the 43rd Annual Meeting of the American Society of Nephrology; November 16, 2010; Denver, CO.
124. Greenbaum LA. Continued improvement in renal function with sustained eculizumab in patients with atypical HUS resistant to plasma exchange/infusion. Paper presented at 44th Annual Meeting of the American Society of Nephrology November 8, 2011; Philadelphia, PA.
125. Licht C. Eculizumab is an effective long-term treatment in patients with atypical haemolytic uremic syndrome previously receiving chronic plasma exchange/infusion: Extension study results. Presented at the 53rd Annual Meeting of the American Society of Hematology; December 10, 2011; San Diego, CA.
126. Legendre C.M., Licht C., Muus P., Greenbaum L.A., Babu S., Bedrosian C., et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. New Engl J Med 2013, 368:2169-2181.
127. Wong EK, Goodship TH, Kavanagh D. Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Mol Immunol. 2013;56:199-212.
128. Bresin E., Daina E., Noris M., Castelletti F., Stefanov R., Hill P., et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol 2006, 1:88-99.
129. Loirat C., Fremeaux-Bacchi V. Hemolytic uremic syndrome recurrence after renal transplantation. Pediatr Transplant 2008, 12:619-629.
130. Fremeaux-Bacchi V., Arzouk N., Ferlicot S., Charpentier B., Snanoudj R., Durrbach A. Recurrence of HUS due to CD46/MCP mutation after renal transplantation: a role for endothelial microchimerism. Am J Transplant 2007, 7:2047-2051.
131. Lorcy N., Rioux-Leclercq N., Lombard M.L., Le Pogamp P., Vigneau C. Three kidneys, two diseases, one antibody?. Nephrol Dial Transplant 2011, 26:3811-3813.
132. Le Quintrec M., Zuber J., Noel L.H., Thervet E., Fremeaux-Bacchi V., Niaudet P., et al. Anti-factor H autoantibodies in a fifth renal transplant recipient with atypical hemolytic and uremic syndrome. Am J Transplant 2009, 9:1223-1229.
133. Kwon T., Dragon-Durey M.A., Macher M.A., Baudouin V., Maisin A., Peuchmaur M., et al. Successful pre-transplant management of a patient with anti-factor H autoantibodies-associated haemolytic uraemic syndrome. Nephrol Dial Transplant 2008, 23:2088-2090.
134. Donne R.L., Abbs I., Barany P., Elinder C.G., Little M., Conlon P., et al. Recurrence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donor. Am J Kidney Dis 2002, 40:E22.
135. Bergstein J., Michael A., Kellstrand C., Simmons R., Najarian J. Hemolytic-uremic syndrome in adult sisters. Transplantation 1974, 17:487-490.
136. Kaplan B.S., Papadimitriou M., Brezin J.H., Tomlanovich S.J., Zulkharnain Renal transplantation in adults with autosomal recessive inheritance of hemolytic uremic syndrome. Am J Kidney Dis 1997, 30:760-765.
137. Remuzzi G., Ruggenenti P., Codazzi D., Noris M., Caprioli J., Locatelli G., et al. Combined kidney and liver transplantation for familial haemolytic uraemic syndrome. Lancet 2002, 359:1671-1672.
138. Remuzzi G., Ruggenenti P., Colledan M., Gridelli B., Bertani A., Bettinaglio P., et al. Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation. Am J Transplant 2005, 5:1146-1150.
139. Cheong H.I., Lee B.S., Kang H.G., Hahn H., Suh K.S., Ha I.S., et al. Attempted treatment of factor H deficiency by liver transplantation. Pediatr Nephrol 2004, 19:454-458.
140. Jalanko H., Peltonen S., Koskinen A., Puntila J., Isoniemi H., Holmberg C., et al. Successful liver-kidney transplantation in two children with aHUS caused by a mutation in complement factor H. Am J Transplant 2008, 8:216-221.
141. Saland J.M., Shneider B.L., Bromberg J.S., Shi P.A., Ward S.C., Magid M.S., et al. Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009, 4:201-206.
142. Haller W., Milford D.V., Goodship T.H., Sharif K., Mirza D.F., McKiernan P.J. Successful isolated liver transplantation in a child with atypical hemolytic uremic syndrome and a mutation in complement factor H. Am J Transplant 2010, 10:2142-2147.
143. Wilson C., Torpey N., Jaques B., Strain L., Talbot D., Manas D., et al. Successful simultaneous liver-kidney transplant in an adult with atypical hemolytic uremic syndrome associated with a mutation in complement factor H. Am J Kidney Dis 2011, 58:109-112.
144. Sanchez-Corral P., Melgosa M. Advances in understanding the aetiology of atypical haemolytic uraemic syndrome. Br J Haematol 2010, 150:529-542.
145. Saland J.M., Emre S.H., Shneider B.L., Benchimol C., Ames S., Bromberg J.S., et al. Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation. Am J Transplant 2006, 6:1948-1952.
146. Kavanagh D., Richards A., Goodship T., Jalanko H. Transplantation in atypical hemolytic uremic syndrome. Semin Thromb Hemost 2010, 36:653-659.
147. Saland J.M., Ruggenenti P., Remuzzi G. Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. J Am Soc Nephrol 2009, 20:940-949.
148. Le Quintrec M., Lionet A., Kamar N., Karras A., Barbier S., Buchler M., et al. Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant 2008, 8:1694-1701.
149. Brown J.H., Tellez J., Wilson V., Mackie I.J., Scully M., Tredger M.M., et al. Postpartum aHUS secondary to a genetic abnormality in factor H acquired through liver transplantation. Am J Transplant 2012, 12:1632-1636.
150. Nuernberger J., Witzke O., Saez A.O., Vester U., Baba H.A., Kribben A., et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 2009, 360:542-544.
151. Al-Akash S.I., Almond P.S., Savell V.H., Gharaybeh S.I., Hogue C. Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation. Pediatr Nephrol 2011, 26:613-619.
152. Chatelet V, Fremeaux-Bacchi V, Lobbedez T, Ficheux M, de Ligny BH. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant. 2009;9:2644-5.
153. Chatelet V., Lobbedez T., Fremeaux-Bacchi V., Ficheux M., Ryckelynck J.P., de Ligny BH. Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report. Transplant Proc 2010, 42:4353-4355.
154. Larrea CF-d Cofan F., Oppenheimer F., Campistol J.M., Escolar G., Lozano M. Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation. Transplantation 2010, 89:903-904.
155. Zuber J., Le Quintrec M., Sberro-Soussan R., Loirat C., Fremeaux-Bacchi V., Legendre C. New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol 2011, 7:23-35.
156. Nester C., Stewart Z., Myers D., Jetton J, Nair R, Reed A, et al. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2011, 6:1488-1494.
157. Krid S., Roumenina L., Beury D., Charbit M., Boyer O., Fremeaux-Bacchi V., et al. Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein. Am J Transplant 2012, 12:1938-1944.
158. Weitz M., Amon O., Bassler D., Koenigsrainer A., Nadalin S. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol 2011, 26:1325-1329.
159. Zimmerhackl L.B., Hofer J., Cortina G., Mark W., Wurzner R., Jungraithmayr T.C., et al. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl J Med 2010, 362:1746-1748.
160. Zuber J., Le Quintrec M., Krid S., Bertoye C., Gueutin V., Lahoche A., et al. Atypical HUS. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant 2012, 12:3337-3354. French Study Group.
161. Roversi P., Johnson S., Caesar J.J., McLean F., Leath K.J., Tsiftsoglou S.A., et al. Structural basis for complement factor I control and its disease-associated sequence polymorphisms. Proc Natl Acad Sci U S A 2011, 108:12839-12844.
162. Sugimoto T., Ogawa N., Aoyama M., Sakaguchi M., Isshiki K., Kanasaki M., et al. Haemolytic uraemic syndrome complicated with norovirus-associated gastroenteritis. Nephrol Dial Transplant 2007, 22:2098-2099.
163. Lee B.H., Kwak S.H., Shin J.I., Lee S.H., Choi H.J., Kang H.G., et al. Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1/CFHR3 deficiency. Pediatr Res 2009, 66:336-340.
164. Carter J.E., Cimolai N. Hemolytic-uremic syndrome associated with acute Campylobacter upsaliensis gastroenteritis. Nephron 1996, 74:489.
165. Alvarado A.S., Brodsky S.V., Nadasdy T., Singh N. Hemolytic uremic syndrome associated with Clostridium difficile infection. Clin Nephrol 2013, (Epub ahead of print).
166. Berner R., Krause M.F., Gordjani N., Zipfel P.F., Boehm N., Krueger M., et al. Hemolytic uremic syndrome due to an altered factor H triggered by neonatal pertussis. Pediatr Nephrol 2002, 17:190-192.
167. Waters A.M., Kerecuk L., Luk D., Haq M.R., Fitzpatrick M.M., Gilbert R.D., et al. Hemolytic uremic syndrome associated with invasive pneumococcal disease: the United Kingdom experience. J Pediatr 2007, 151:140-144.
168. Chand D.H., Brady R.C., Bissler J.J. Hemolytic uremic syndrome in an adolescent with Fusobacterium necrophorum bacteremia. Am J Kidney Dis 2001, 37:E22.
169. Kwon T., Belot A., Ranchin B., Baudouin V., Fremeaux-Bacchi V., Dragon-Durey M.A., et al. Varicella as a trigger of atypical haemolytic uraemic syndrome associated with complement dysfunction: two cases. Nephrol Dial Transplant 2009, 24:2752-2754.
170. Waiser J., Budde K., Rudolph B., Ortner M.A., Neumayer H.H. De novo hemolytic uremic syndrome postrenal transplant after cytomegalovirus infection. Am J Kidney Dis 1999, 34:556-559.
171. Bento D., Mapril J., Rocha C., Marchbank K.J., Kavanagh D., Barge D., et al. Triggering of atypical hemolytic uremic syndrome by influenza A (H1N1). Ren Fail 2010, 32:753-756.
172. Tagle M., Barriga J.A., Gutierrez S., Valdez L.M., Castle J., Antunez De Mayolo A., et al. [Relapsing viral hepatitis type A complicated with renal failure]. Rev Gastroenterol Peru 2004, 24:92-96.
173. Baid S., Pascual M., Williams W.W., Tolkoff-Rubin N., Johnson S.M., Collins B., et al. Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients. J Am Soc Nephrol 1999, 10:146-153.
174. Benitez M., Boto A., Colchero J., Fernandez-Giron F., Rodriguez P., Paralle M., et al. Haemolytic-uraemic syndrome in a patient infected by HIV. Nephrol Dial Transplant 1997, 12:362-363.
175. Austin T.W., Ray C.G. B infections and the hemolytic-uremic syndrome. J Infect Dis 1973, 127:698-701. Coxsackie virus group.
176. Watanabe T. Hemolytic uremic syndrome associated with Epstein-Barr virus infection. Pediatr Nephrol 2004, 19:569.
177. Wiersinga W.J., Scheepstra C.G., Kasanardjo J.S., de Vries PJ, Zaaijer H, Geerlings SE. Dengue fever-induced hemolytic uremic syndrome. Clin Infect Dis 2006, 43:800-801.
178. Matsuda Y., Hara J., Miyoshi H., Osugi Y., Fujisaki H., Takai K., et al. Thrombotic microangiopathy associated with reactivation of human herpesvirus-6 following high-dose chemotherapy with autologous bone marrow transplantation in young children. Bone Marrow Transplant 1999, 24:919-923.
179. Hartel C., Herz A., Vieth S., Lensing C., Schultz C. Renal complications associated with human parvovirus B19 infection in early childhood. Klin Padiatr 2007, 219:74-75.
180. Adonis-Koffy L. [May Plasmodium falciparum induce a hemolytic uremic syndrome?]. Arch Pediatr 2004, 11:55-56.
181. Noris M., Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009, 361:1676-1687.
182. Canpolat C., Pearson P., Jaffe N. Cisplatin-associated hemolytic uremic syndrome. Cancer 1994, 74:3059-3062.
183. Boeck S., Geiger S., Schulz C., Heinemann V. Hemolytic-uremic syndrome associated with gemcitabine treatment for metastatic pancreatic cancer. J Clin Gastroenterol 2008, 42:551-552.
184. Ariyoshi K., Shinohara K., Ruirong X. Thrombotic thrombocytopenic purpura caused by ticlopidine, successfully treated by plasmapheresis. Am J Hematol 1997, 54:175-176.
185. Andersohn F., Hagmann F.G., Garbe E. Thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome associated with clopidogrel: report of two new cases. Heart 2004, 90:e57.
186. Aster R.H. Quinine sensitivity: a new cause of the hemolytic uremic syndrome. Ann Intern Med 1993, 119:243-244.
187. Gottschall J.L., Neahring B., McFarland J.G., Wu G.G., Weitekamp L.A., Aster R.H. Quinine-induced immune thrombocytopenia with hemolytic uremic syndrome: clinical and serological findings in nine patients and review of literature. Am J Hematol 1994, 47:283-289.
188. Ubara Y., Hara S., Takedatu H., Katori H., Yamada K., Yoshihara K., et al. Hemolytic uremic syndrome associated with beta-interferon therapy for chronic hepatitis C. Nephron 1998, 80:107-108.
189. Badid C., McGregor B., Faivre J.M., Guerard A., Juillard L., Fouque D., et al. Renal thrombotic microangiopathy induced by interferon-alpha. Nephrol Dial Transplant 2001, 16:846-848.
190. Keir L., Moorsel F., Saleem M.A., Richards A. Beware renal adverse effects of anti-vascular endothelial growth factor treatment. BMJ 2012, 344:e3838.
191. Bonatti H., Brandacher G., Boesmueller C., Cont M., Hengster P., Rosenkranz A.R., et al. Hemolytic uremic syndrome following Campath-1H induction. Transpl Int 2007, 20:386-389.
192. Abraham K.A., Little M.A., Dorman A.M., Walshe J.J. Hemolytic-uremic syndrome in association with both cyclosporine and tacrolimus. Transpl Int 2000, 13:443-447.
193. Allan D.S., Thompson C.M., Barr R.M., Clark W.F., Chin-Yee I.H. Ciprofloxacin-associated hemolytic-uremic syndrome. Ann Pharmacother 2002, 36:1000-1002.
194. Blumberg A., Studer U., Briner J. [Hemolytic-uremic syndrome in a young woman following the use of ovulation inhibitors]. Schweiz Med Wochenschr 1975, 105:1324-1327.
195. Ashouri O.S., Marbury T.C., Fuller T.J., Gaffney E., Grubb W.G., Cade J.R. Hemolytic uremic syndrome in two postmenopausal women taking a conjugated estrogen preparation. Clin Nephrol 1982, 17:212-215.
196. Au W.Y., Chan K.W., Lam C.C., Young K. A post-menopausal woman with anuria and uterus bulk: the spectrum of estrogen-induced TTP/HUS. Am J Hematol 2002, 71:59-60.
197. Tumlin J.A., Sands J.M., Someren A. Hemolytic-uremic syndrome following "crack" cocaine inhalation. Am J Med Sci 1990, 299:366-371.
198. Ardiles L.G., Olavarria F., Elgueta M., Moya P., Mezzano S. Anticardiolipin antibodies in classic pediatric hemolytic-uremic syndrome: a possible pathogenic role. Nephron 1998, 78:278-283.
199. Barre P., Kaplan B.S., de Chadarevian JP, Drummond KN. Hemolytic uremic syndrome with hypocomplementemia, serum C3NeF, and glomerular deposits of C3. Arch Pathol Lab Med 1977, 101:357-361.
200. Nesher G., Hanna V.E., Moore T.L., Hersh M., Osborn T.G. Thrombotic microangiographic hemolytic anemia in systemic lupus erythematosus. Semin Arthritis Rheum 1994, 24:165-172.
201. Hale G.A., Bowman L.C., Rochester RJ, Benaim E, Heslop HE, Krance RA, et al. Hemolytic uremic syndrome after bone marrow transplantation: clinical characteristics and outcome in children. Biol Blood Marrow Transplant 2005, 11:912-920.
202. Lechner K., Obermeier H.L. Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases. Medicine (Baltimore) 2012, 91:195-205.
203. Kind T., Levy J., Lee M., Kaicker S., Nicholson J.F., Kane S.A. Cobalamin C disease presenting as hemolytic-uremic syndrome in the neonatal period. J Pediatr Hematol Oncol 2002, 24:327-329.
204. Lehtinen M.J., Rops A.L., Isenman D.E., van der Vlag J., Jokiranta T.S. Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome. J Biol Chem 2009, 284:15650-15658.
205. Morgan H.P., Schmidt C.Q., Guariento M., Blaum B.S., Gillespie D., Herbert A.P., et al. Structural basis for engagement by complement factor H of C3b on a self surface. Nat Struct Mol Biol 2011, 18:463-470.
206. Jozsi M., Heinen S., Hartmann A., Ostrowicz C.W., Halbich S., Richter H., et al. Factor H and atypical hemolytic uremic syndrome: mutations in the C-terminus cause structural changes and defective recognition functions. J Am Soc Nephrol 2006, 17:170-177.
207. Jokiranta T.S., Cheng Z.Z., Seeberger H., Jozsi M., Heinen S., Noris M., et al. Binding of complement factor H to endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site. Am J Pathol 2005, 167:1173-1181.
208. Manuelian T., Hellwage J., Meri S., Caprioli J., Noris M., Heinen S., et al. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest 2003, 111:1181-1190.
209. Sanchez-Corral P., Gonzalez-Rubio C., Rodriguez de Cordoba S, Lopez-Trascasa M. Functional analysis in serum from atypical hemolytic uremic syndrome patients reveals impaired protection of host cells associated with mutations in factor H. Mol Immunol 2004, 41:81-84.
210. Sanchez-Corral P., Perez-Caballero D., Huarte O., Simckes A.M., Goicoechea E., Lopez-Trascasa M., et al. Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome. Am J Hum Genet 2002, 71:1285-1295.
211. Morgan H.P., Jiang J., Herbert A.P., Kavanagh D., Uhrin D., Barlow P.N., et al. Crystallographic determination of the disease-associated T1184R variant of complement regulator factor H. Acta Crystallogr D Biol Crystallogr 2011, 67:593-600.
212. Herbert A.P., Kavanagh D., Johansson C., Morgan H.P., Blaum B.S., Hannan J.P., et al. Structural and functional characterization of the product of disease-related factor H gene conversion. Biochemistry 2012, 51:1874-1884.
213. Boyer O., Balzamo E., Charbit M., Biebuyck-Gouge N., Salomon R., Dragon-Durey M.A., et al. Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies. Am J Kidney Dis 2010, 55:923-927.
214. Geelen J., van den Dries K., Roos A., van de Kar N, de Kat Angelino C, Klasen I, et al. A missense mutation in factor I (IF) predisposes to atypical haemolytic uraemic syndrome. Pediatr Nephrol 2007, 22:371-375.
215. Chan M.R., Thomas C.P., Torrealba J.R., Djamali A., Fernandez L.A., Nishimura C.J., et al. Recurrent atypical hemolytic uremic syndrome associated with factor I mutation in a living related renal transplant recipient. Am J Kidney Dis 2009, 53:321-326.
216. Cayci F.S., Cakar N., Hancer V.S., Uncu N., Acar B., Gur G. Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation. Pediatr Nephrol 2012, 27:2327-2331.
217. Fang C.J., Fremeaux-Bacchi V., Liszewski M.K., Pianetti G., Noris M., Goodship T.H., et al. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood 2008, 111:624-632.
218. Noris M., Brioschi S., Caprioli J., Todeschini M., Bresin E., Porrati F., et al. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 2003, 362:1542-1547.
219. Fremeaux-Bacchi V., Sanlaville D., Menouer S., Blouin J., Dragon-Durey M.A., Fischbach M., et al. Unusual clinical severity of complement membrane cofactor protein-associated hemolytic-uremic syndrome and uniparental isodisomy. Am J Kidney Dis 2007, 49:323-329.
220. Volokhina E., Westra D., Xue X., Gros P., van de Kar N, van den Heuvel L. Novel C3 mutation p.Lys65Gln in aHUS affects complement factor H binding. Pediatr Nephrol 2012, 27:1519-1524.
221. Malina M., Gulati A., Bagga A., Majid M.A., Simkova E., Schaefer F. Peripheral gangrene in children with atypical hemolytic uremic syndrome. Pediatrics 2013, 131:e331-e335.
222. Ozel A., Caliskan U., Gucer S. Peripheral gangrene complicating hemolytic uremic syndrome in a child. Pediatr Nephrol 2003, 18:465-467.
223. Kaplan B.S., Garcia C.D., Chesney R.W., Segar W.E., Giugno K., Chem R. Peripheral gangrene complicating idiopathic and recessive hemolytic uremic syndromes. Pediatr Nephrol 2000, 14:985-989.
224. Loirat C., Macher M.A., Elmaleh-Berges M., Kwon T., Deschenes G., Goodship T.H., et al. Non-atheromatous arterial stenoses in atypical haemolytic uraemic syndrome associated with complement dysregulation. Nephrol Dial Transplant 2010, 25:3421-3425.
225. Vergouwen M.D., Adriani K.S., Roos Y.B., Groothoff J.W., Majoie C.B. Proximal cerebral artery stenosis in a patient with hemolytic uremic syndrome. AJNR Am J Neuroradiol 2008, 29:e34.
226. Sallee M., Daniel L., Piercecchi M.D., Jaubert D., Fremeaux-Bacchi V., Berland Y, et al. Myocardial infarction is a complication of factor H-associated atypical HUS. Nephrol Dial Transplant 2010, 25:2028-2032.
227. Larakeb A., Leroy S., Fremeaux-Bacchi V., Montchilova M., Pelosse B., Dunand O., et al. Ocular involvement in hemolytic uremic syndrome due to factor H deficiency--are there therapeutic consequences?. Pediatr Nephrol 2007, 22:1967-1970.